IPO - MED-X, INC.

Form Type: 253G3

Filing Date: 2025-06-03

Corporate Action: Ipo

Type: New

Accession Number: 000147793225004379

Filing Summary: Med-X, Inc. is offering 2,500,000 shares of common stock at $4.00 per share, aiming to raise $10,000,000 before offering expenses. The offering is directed at sophisticated investors and will commence following SEC qualification. As of June 2, 2025, there are 21,706,015 shares outstanding. The offering circulates according to Rule 253(g)(3) and reflects an exemption from registration with the SEC. Dealmaker Securities LLC has been engaged as the lead selling agent, receiving a commission of 4.5% on sales. The offering terminates upon the sale of all shares, one year post SEC qualification, or at the company’s discretion. Historical highlights include the 2018 acquisition of Pacific Shore Holdings, enhancing Med-X’s product portfolio and distribution network. Recent developments showcase international expansion initiatives for Nature-Cide products, active product development, partnerships aimed at financial growth, and strategic marketing enhancements on their media platform, The MJT Network. The financial summary indicates expected expenses of approximately $815,000 for the maximum offering amount, with a significant focus on operational efficiencies and a risk factors section stressing the speculative nature of the offering.